Clinical Trial Update: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection [Phase 3]

View source ↗

Summary

This is an update on a Phase 3 trial evaluating AK104 as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence after curative resect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: RECRUITING